Hyperphosphatemia - Pipeline Review, H2 2015

Date: July 15, 2015
Pages: 82
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H16D28D3F3EEN
Leaflet:

Download PDF Leaflet

Hyperphosphatemia - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Hyperphosphatemia - Pipeline Review, H2 2015’, provides an overview of the Hyperphosphatemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperphosphatemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hyperphosphatemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hyperphosphatemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hyperphosphatemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hyperphosphatemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Hyperphosphatemia Overview
Therapeutics Development
Pipeline Products for Hyperphosphatemia - Overview
Pipeline Products for Hyperphosphatemia - Comparative Analysis
Hyperphosphatemia - Therapeutics under Development by Companies
Hyperphosphatemia - Therapeutics under Investigation by Universities/Institutes
Hyperphosphatemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Hyperphosphatemia - Products under Development by Companies
Hyperphosphatemia - Products under Investigation by Universities/Institutes
Hyperphosphatemia - Companies Involved in Therapeutics Development
3SBIO INC.
Ardelyx, Inc.
Galenica Ltd.
Medice Arzneimittel Putter GmbH & Co. KG
OPKO Health, Inc.
Panion & Bf Biotech Inc
Sanofi
Spectrum Pharmaceuticals, Inc.
Toray Industries, Inc.
Hyperphosphatemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
colestilan chloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPAM-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fermagate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ferric citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
calcium succinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JPH-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
niacinamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PDX-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PT-20 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RDX-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sevelamer carbonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target Phosphate for Hyperphosphatemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SPI-014 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
succharated ferric oxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tenapanor hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TRK-390 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS-505 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hyperphosphatemia - Recent Pipeline Updates
Hyperphosphatemia - Dormant Projects
Hyperphosphatemia - Discontinued Products
Hyperphosphatemia - Product Development Milestones
Featured News & Press Releases
Mar 04, 2015: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Analysis in Journal of the American Society of Nephrology
Feb 02, 2015: Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis
Jan 27, 2015: Velphoro receives Swissmedic approval for the treatment of hyperphosphatemia in adult patients with chronic kidney disease on dialysis
Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch
Dec 04, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Auryxia (ferric citrate) Covering Orally Administrable Forms
Nov 19, 2014: New Drug Application Submitted For PA21 (development code) For Treatment Of Hyperphosphatemia
Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate
Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
Oct 23, 2014: Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014
Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hyperphosphatemia, H2 2015
Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Hyperphosphatemia - Pipeline by 3SBio Inc., H2 2015
Hyperphosphatemia - Pipeline by Ardelyx, Inc., H2 2015
Hyperphosphatemia - Pipeline by Galenica Ltd., H2 2015
Hyperphosphatemia - Pipeline by Medice Arzneimittel Putter GmbH & Co. KG, H2 2015
Hyperphosphatemia - Pipeline by OPKO Health, Inc., H2 2015
Hyperphosphatemia - Pipeline by Panion & Bf Biotech Inc, H2 2015
Hyperphosphatemia - Pipeline by Sanofi, H2 2015
Hyperphosphatemia - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
Hyperphosphatemia - Pipeline by Toray Industries, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Hyperphosphatemia Therapeutics - Recent Pipeline Updates, H2 2015
Hyperphosphatemia - Dormant Projects, H2 2015
Hyperphosphatemia - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Hyperphosphatemia, H2 2015
Number of Products under Development for Hyperphosphatemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015
Skip to top


Ask Your Question

Hyperphosphatemia - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: